299. Cystic fibrosis Clinical trials / Disease details
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00903201 (ClinicalTrials.gov) | September 28, 2009 | 14/5/2009 | 28 Day Repeat Dose in Cystic Fibrosis Patients | A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis. | Cystic Fibrosis | Drug: SB656933;Drug: Placebo | GlaxoSmithKline | NULL | Completed | 18 Years | N/A | All | 146 | Phase 2 | United States;Canada;France;Germany;Israel |
| 2 | NCT00605761 (ClinicalTrials.gov) | February 2008 | 18/1/2008 | SD Cystic Fibrosis Study | An Open Label Dose Ascending, Single Dose Study to Investigate the Pharmacokinetics of SB-656933 in Subjects With Cystic Fibrosis. | Cystic Fibrosis | Drug: SB656933 | GlaxoSmithKline | NULL | Completed | 16 Years | N/A | Both | 9 | Phase 1 | United States |